详情页 - 昆明医科大学第一附属医院知识库

当前位置：首页 > 详情页

Complement Factor B (CFB) inhibits the malignant progression of lung adenocarcinoma by downregulating the Ras/MAPK signaling pathway

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Clinical Laboratory, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, Yunnan, China [2]Yunnan Key Laboratory of Laboratory Medicine, Kunming, 650032, Yunnan, China [3]Yunnan Province Clinical Research Center for Laboratory Medicine, Kunming, 650032, China

出处：

DOI：

ISSN：

关键词： Complement factor B Lung adenocarcinoma Ras/MAPK

摘要：

Lung adenocarcinoma (LUAC) as the most common lung cancer, and its incidence is increasing. Complement factor B (CFB) is an important factor in the alternative complement pathway. CFB has been reported to be involved in the progression of many cancers, including in pancreatic cancer, cutaneous squamous cell carcinoma, and nasopharyngeal carcinoma, but the function and molecular mechanism of CFB in LUAC remains unclear. The present study aimed to explore the role of CFB in LUAC malignant progression. In our previous study, we found that CFB was downregulated expression in LUAC clinical samples. Here, we firstly detected the cell function in vitro. Cell proliferation and migration were increased, while cell apoptosis and cell cycle arrest were suppressed after CFB knockdown. Overexpression of CFB repressed the malignant progression of LUAC in vitro. Besides, in vivo experiments revealed that upregulation of CFB inhibited tumor growth and Ki67 expression. Additionally, our data indicated that CFB negatively regulated Ras/mitogen-activated protein kinase (MAPK) signaling pathway. Furthermore, upregulation of CFB inhibited the progression of LUAC was reversed by Ras/MAPK pathway activators (ML-098 or C16-PAF). Our study uncovered that CFB acts as a tumor suppressor repressed tumorigenesis of LUAC through inhibiting the Ras/MAPK pathway, suggesting that CFB may be a potential biomarker and therapeutic target for LUAC.Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

无

最新[2023]版：

大类 | 3 区生物学

小类 | 2 区生物物理 3 区生化与分子生物学

第一作者：

第一作者机构： [1]Department of Clinical Laboratory, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, Yunnan, China [2]Yunnan Key Laboratory of Laboratory Medicine, Kunming, 650032, Yunnan, China [3]Yunnan Province Clinical Research Center for Laboratory Medicine, Kunming, 650032, China

共同第一作者：

通讯作者：

通讯机构： [1]Department of Clinical Laboratory, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, Yunnan, China [2]Yunnan Key Laboratory of Laboratory Medicine, Kunming, 650032, Yunnan, China [3]Yunnan Province Clinical Research Center for Laboratory Medicine, Kunming, 650032, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Low CFB expression is independently associated with poor overall and disease-free survival in patients with lung adenocarcinoma [2]Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma [3]A new biomarker of microbe: Akkermansia muciniphila in lung adenocarcinoma tissues may predict lymph node metastasis in lung adenocarcinoma [4]Whole genome sequencing analysis of lung adenocarcinoma in Xuanwei, China [5]Gene expression profiling of lung adenocarcinoma in Xuanwei, China [6]CBX7, a Potential Prognostic Biomarker in Lung Adenocarcinoma [7]Extra Spindle Pole Bodies-Like 1 Serves as a Prognostic Biomarker and Promotes Lung Adenocarcinoma Metastasis [8]Bioinformatics Identification of Key Genes for the Development and Prognosis of Lung Adenocarcinoma [9]非小细胞肺癌A549和H520细胞PDCD4和AP-1表达与细胞迁移的相关性研究 [10]Association Analysis of Nonsyndromic Congenital Heart Disease and Tag Single Nucleotide Polymorphisms of TBX20 and Genes in the Ras-MAPK Pathway